Relugolix in treatment of prostate cancer: a review
Relugolix represents a significant advancement in ADT, offering a potent, oral alternative with a rapid onset of action, a superior cardiovascular safety profile, and improved testosterone recovery. It provides clinicians with a valuable option for treating advanced prostate cancer, particularly in patients with cardiovascular comorbidities.
Authors
- Themistoklis Bellos (ORCID: https://orcid.org/0000-0002-0390-1467)
- Athanasios Papatsoris (ORCID: https://orcid.org/0000-0003-2277-1175)
- Panagiotis Angelopoulos (ORCID: https://orcid.org/0000-0003-0180-4476)
- Stamatios Katsimperis (ORCID: https://orcid.org/0000-0002-7028-1544)
- Andreas Skolarikos (ORCID: https://orcid.org/0000-0002-8338-6628)
- Ioannis Varkarakis (ORCID: https://orcid.org/0000-0002-9248-7404)
- Ioannis Kyriazis (ORCID: https://orcid.org/0009-0003-4505-5574)
- Panagiotis Neofytoy
Institutions
- Sismanoglio General Hospital (GR)
- Hellenic Red Cross (GR)
Publication Details
- Journal
- Archivio Italiano di Urologia e Andrologia
- Published
- 2025-11-13
- DOI
- https://doi.org/10.4081/aiua.2025.14277
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52